碘油肝动脉栓塞化疗对肝癌：疗效和安全性数据的系统评价

StephenW

Hepatobiliary Malignancies
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
Authors

    Accepted manuscript online: 13 January 2016Full publication history
    DOI: 10.1002/hep.28453View/save citation
    Cited by: 0 articles last updated 16 January 2016
    Article has an altmetric score of 3

Abstract

Transarterial chemoembolization (TACE) using Lipiodol-based regimens including the administration of an anticancer-in-oil emulsion followed by embolic agents is widely used in the treatment of hepatocellular carcinoma (HCC). This approach has been supported by meta-analyses of randomized controlled trials (RCTs) performed more than a decade ago. We performed a systematic review to understand current efficacy and safety data of Lipiodol TACE in treatment of HCC. A search of the literature published between January 1, 1980, and June 30, 2013 was performed using MEDLINE and EMBASE databases. All potentially relevant publications were reviewed and articles were selected based on pre-defined inclusion and exclusion criteria. Out of a total of 1,564 articles reviewed, 101 articles including a total of 10,108 patients treated with Lipiodol TACE were selected for the efficacy analysis. Objective response rate was 52.5% (95% confidence interval, 43.6% – 61.5%). Overall survival was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years. Median overall survival was 19.4 months (95% confidence interval, 16.2 – 22.6). A total of 217 articles presenting precise description on numbers of adverse events (AEs) were selected for the safety review: in these studies, a total of 21,461 AEs were reported in 15,351 patients. Liver enzyme abnormalities were the most commonly observed AE, followed by the symptoms associated with post-embolization syndrome. The overall mortality rate was 0.6% and the most common cause of death was related to acute liver insufficiency. Conclusion: in a systematic literature review, survival figures of HCC patients undergoing Lipiodol TACE appear to be in line with those reported in previous RCTs, and no new or unexpected safety concerns were identified. This article is protected by copyright. All rights reserved.

StephenW

肝胆恶性肿瘤
碘油肝动脉栓塞化疗对肝癌：疗效和安全性数据的系统评价
作者接受稿件在线：2016年1月13日全部公开历史DOI：0文章最后更新2016年1月16日文章有altmetric比分3：10.1002 / hep.28453查看/保存引文通过引
抽象
采用碘油为基础的方案包括一种抗癌的油乳液，然后栓塞剂的施用化学栓塞（TACE）被广泛用于肝细胞癌（HCC）的药物。这种方法已经被随机对照试验（RCT）的荟萃分析的支持进行了超过十年前。我们进行了系统的审查，以了解治疗肝癌碘油栓塞当前有效性和安全性数据。使用MEDLINE和医学文摘数据库进行搜索1980年1月1日，和2013年6月30日之间出版的文献。所有可能相关的出版物进行了审查，并根据预先定义的入选和排除标准的文章被选中。在总共1,564篇评论中，有101条共包括10108例碘油栓塞治疗被选定为疗效分析。客观缓解率为52.5％（95％置信区间，43.6％， - 61.5％）。总体生存率为1年70.3％，在2年51.8％，在3年40.4％，并在5年为32.4％。中位总生存期为19.4个月（95％置信区间，16.2 - 22.6）。共有217篇对不良事件（AE）的数量呈现精确的描述被选定为安全审查：在这些研究中，一共有21461不良事件报告15,​​351例。肝酶异常是最通常观察到的AE，接着用后栓塞症相关的症状。总死亡率为0.6％和死亡的最常见的原因是与急性肝机能不全。结论：在一个系统的文献综述，肝癌患者接受碘油TACE的生存数字似乎是与文献报道在前面的随机对照试验线，也没有新的或意外的安全问题进行了鉴定。这篇文章是受版权保护的。版权所有。